Cargando…

Status of programmed death-ligand 1 expression in sarcomas

BACKGROUND: Sarcomas are challenging to study because of their rarity and histomorphological complexity. PD1 and PD-L1 inhibitors showed a promising anti-tumor effect in solid tumors, where a relationship between PD-L1 expression and the objective response has been evidenced. METHODS: In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyung Kyu, Kim, Mingi, Sung, Minjung, Lee, Seung Eun, Kim, Yu Jin, Choi, Yoon-La
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219031/ https://www.ncbi.nlm.nih.gov/pubmed/30400799 http://dx.doi.org/10.1186/s12967-018-1658-5

Ejemplares similares

Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
por: Kim, Yu Jin, et al.
Publicado: (2019)

Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis
por: Go, Du-Min, et al.
Publicado: (2021)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
por: Kim, Hyung Suk, et al.
Publicado: (2020)

Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus
por: Park, Min-Jung, et al.
Publicado: (2021)

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
por: Park, Dong-Jun, et al.
Publicado: (2021)

Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis
por: Lee, Kyu Sang, et al.
Publicado: (2018)

Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
por: Park, Ha-Young, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
por: Choi, Hyungwook, et al.
Publicado: (2023)

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
por: Cho, Junhun, et al.
Publicado: (2017)

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
por: Kim, Ryul, et al.
Publicado: (2016)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer
por: Bae, Sung Uk, et al.
Publicado: (2018)

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent
por: van Erp, Anke E.M., et al.
Publicado: (2017)

T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas
por: Pollack, Seth M., et al.
Publicado: (2017)

The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer
por: Kwon, Sung Chan, et al.
Publicado: (2023)

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2017)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
por: Kim, Ji Hye, et al.
Publicado: (2020)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma
por: Sung, Pil Soo, et al.
Publicado: (2020)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas
por: Rajendran, Madhubala, et al.
Publicado: (2023)

Molecular changes in solitary fibrous tumor progression
por: Park, Hyung Kyu, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis
por: Kim, Hye Min, et al.
Publicado: (2017)

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)

Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
por: An, Hyo Jung, et al.
Publicado: (2018)

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
por: Kang, Minsu, et al.
Publicado: (2021)

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
por: Lee, Seung Eun, et al.
Publicado: (2019)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3‐mediated programmed death‐ligand 1 expression in colorectal cancer
por: Min, Hye‐Young, et al.
Publicado: (2022)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

NTRK Fusions in 1113 Solid Tumors in a Single Institution
por: Bang, Heejin, et al.
Publicado: (2022)

Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer
por: Noh, Myung-Giun, et al.
Publicado: (2021)

Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer
por: Yeo, Chang Dong, et al.
Publicado: (2019)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cm0d4gaqja4em5t88urrl5jpjr